the dsip record, / read like a reel

The short version

DSIP — Delta Sleep-Inducing Peptide — is a nine-amino-acid molecule first isolated from the blood of sleeping rabbits in 1977 and named for the slow delta brain waves it boosted. It is found naturally in blood, spinal fluid, and even breast milk. Despite five decades of study, no one has found the receptor it acts through, the gene that codes it, or a complete explanation of how it works.

The honest upshot: DSIP is a research peptide with genuinely interesting pilot findings in sleep, withdrawal, and stress biology, but its effects in people are inconsistent and its mechanism remains, in the literature's own words, an unresolved riddle. A large share of people who try it report no effect at all. This site is a cited, indexed review of what the research actually shows — including the gaps. For what people report and what to watch for, see the effects page.

What Is DSIP?

Delta Sleep-Inducing Peptide (DSIP) is a nonapeptide — nine amino acids, sequence WAGGDASGE — first isolated from rabbit cerebral venous blood by Schoenenberger and Monnier in 1974 while studying electrically-induced sleep ^[1]. Its molecular weight is approximately 850 daltons, and it has since been identified under the INN designation Emideltide in regulatory contexts.

What made DSIP immediately interesting was not just what it did, but where it was found. The peptide is present endogenously across the hypothalamus, limbic system, pituitary, peripheral organs, gut secretory cells, human breast milk, cerebrospinal fluid, plasma, and urine ^[1]. That widespread distribution pointed investigators toward functions well beyond simple sleep induction — a signal confirmed by five decades of follow-on research.

DSIP crosses the blood-brain barrier (BBB) via a saturable, high-affinity transport mechanism ^[1]. This is unusual: most peptides of similar size cannot traverse the BBB at all. The amphiphilic character of the molecule — it has both water-attracting and water-repelling regions — is thought to facilitate passage across biological membranes.

What the Research Record Shows

The DSIP literature is a five-decade arc that began with animal sleep pharmacology, moved into small human pilot trials in the 1980s, expanded into withdrawal medicine and neuroendocrinology, then broadened further into geroprotective biology and, most recently, stroke recovery and engineered delivery systems.

Sleep and slow-wave architecture. Intravenous DSIP administration produced multi-hour sleep in rabbits, rats, mice, and cats in structure-activity studies that showed the effect was highly sequence-specific — single amino acid substitutions abolished it ^[1]. In a double-blind placebo-controlled study of chronic insomniacs, DSIP at 25 nmol/kg improved sleep efficiency and shortened sleep latency versus placebo ^[15]. A seven-night course in 14 middle-aged chronic insomniacs produced substantial improvements from the first dose, with daytime alertness and performance increasing significantly and sleep efficiency reaching normal-control levels ^[3].

Withdrawal symptom alleviation. In 67 patients with acute withdrawal (28 alcohol-dependent, 39 opioid-dependent), DSIP at 25 nmol/kg intravenously alleviated somatic withdrawal signs in 48 of 49 evaluable subjects — a 98% alleviation rate — with immediate onset and no major adverse events ^[4].

Beyond sleep. Animal research has documented anticonvulsant effects in a rat epilepsy model ^[7], growth hormone stimulation via hypothalamic dopaminergic mediation ^[8], LH release without FSH effect ^[12], antioxidant enzyme upregulation in aging rats ^[13], mitochondrial respiratory protection under hypoxia ^[10], and accelerated motor-function recovery after experimental stroke ^[14]. A 2024 study demonstrated that a DSIP fusion peptide engineered for BBB penetration reduced wakefulness by 31% in an insomnia mouse model and restored neurotransmitter balance across serotonin, melatonin, and dopamine pathways ^[17].

Regulatory status. DSIP (Emideltide) was placed on the FDA's Category 2 bulk drug substances list in September 2023, citing immunogenicity concerns. A formal reassessment by the Pharmacy Compounding Advisory Committee (PCAC) is scheduled for July 24, 2026 (docket FDA-2025-N-6895), reviewing potential inclusion on the Section 503A Bulk Drug Substances list for compounding use in opioid withdrawal, chronic insomnia, and narcolepsy.

How to Navigate This Site

This site presents the DSIP research record in seven indexed chapters. /research covers mechanism of action and the primary study findings in depth. /dosage documents the dose parameters used in research contexts — this is research-context framing only, not clinical guidance. /faq addresses the most common questions the published literature can actually answer. /references lists every citation with DOI, PMID, and outbound links to primary sources. /about explains the editorial standards and nature of this publication. /contact is available for editorial feedback.

Every quantitative claim on this site is sourced directly from peer-reviewed publications or official regulatory records. Where the evidence is limited, uncertain, or contested, the text says so.

A Note on Research Status

DSIP is a research peptide that has not been approved by the FDA for any therapeutic indication. Most of the human clinical data available comes from small pilot studies conducted in the 1980s and 1990s — rigorous by the standards of their time, but not replicated in large modern randomized controlled trials. The mechanistic picture is also incomplete: no gene encoding DSIP has been identified in rabbits or humans, no dedicated receptor has been characterized, and the question of how a peptide with a 15-minute in vitro brain half-life exerts effects lasting hours remains open ^[1][18].

Those gaps are part of the story. This site presents them alongside the positive findings, because the research record is what it is — neither more nor less.